A controlled trial of antidepressants in patients with Parkinson disease and depression

Neurology

Volumn 72, Issue 10, 2009, Pages 886-892

  Menza, M ^a,b   Dobkin, R D ^a   Marin, H ^a,b   Mark, M H ^a   Gara, M ^a,b   Buyske, S ^c   Bienfait, K ^a   Dicke, A ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORTRIPTYLINE; PAROXETINE; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP; SOCIAL INTERACTION; SYNCOPE; UNITED STATES; XEROSTOMIA; COGNITION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY; COGNITION; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NORTRIPTYLINE; PARKINSON DISEASE; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SLEEP; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 64049105010     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000336340.89821.b3     Document Type: Article

References (37)

1. Menza M, Marsh L, eds. Psychiatric Issues in Parkinson's Disease: A Practical Guide. London: Taylor & Francis; 2006.
2. Reijnders MA, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord Epub 2007 Nov 6.
3. Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, Elm J. The impact of depressive symptoms in early Parkinson disease. Neurology 2007;69:342-347.
4. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997;45: 844-849.
5. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006;248:151-157.
6. Global Parkinson's Disease Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002;17:60-67.
7. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and metaanalysis. Mov Disord 2005;20:1161-1169.
8. Ghaxi-Noori S, Chung TH, Deane KHO, Rickards H, Clarke CE. Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 2003;3:CD003465.
9. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Neurology 1997;49:1168-1170.
10. Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM. Antidepressant treatment of veterans with Parkinson's disease and depression: Analysis of a national sample. J Geriatr Psychiatry Neurol 2007;20:161-165.
11. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol 1990;53:245-249.
12. First MB, Spritzer RL, Gibbon M. Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition, Biometrics Research Department. New York: New York State Psychiatric Institute; 1995.
13. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
15. Hamilton M. Hamilton Depression Scale. In: ECDEU Assessment Manual for Psychopharmacology, revised edition. Rockville, MD: National Institute of Mental Health; 1976: 179-192.
16. Jenkinson CR. The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychol Health 1997;12:805-814.
17. Jenkinson C, Coulter A, Wright L. Short Form 36 (SF 36) Health Survey Questionnaire; normative data for adults of working age. BMJ 1993;306:1437-1440.
18. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976.
19. Hamilton M. The assessment of anxiety status by rating. Br J Med Psychol 1959;32:50-55.
20. Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res 1998;45(1 Spec No):5-13.
21. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987: 153-164.
22. Wechsler D. Wechsler Adult Intelligence Test (Third Edition). New York: Psychological Corporation; 1997.
23. Kaplan EF, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia: Lee & Febiger; 1983.
24. Wechsler D. Wechsler Memory Scale (Third Edition). New York: Psychological Corporation; 1997.
25. Golden CJ. Stroop Color and Word Test. Wood Dale, IL: Stoelting Co.; 1978:1-32.
26. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer; 2000.
27. Bump GM, Mulsant BH, Pollock BG, et al. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety 2001;13:38-44.
28. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000;157:351-359.
29. Anderson J, Aabro E, Gulmann AE, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 1980;62:210-219.
30. Remy P, Doder M, Lees A, Turjanki N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline noradrenaline innervation in the limbic system. Brain 2005; 128:1314-1322.
31. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Current Pharma Des 2005;11:999-1016.
32. Morón JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002;22:389-395.
33. Valentini V, Frau R, Di Chiara G. Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J Neurochem 2004;88: 917-927.
34. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with paroxetine: a placebo-controlled trial. Nord J Psychiatry 1998;52:163-169.
35. Leentjens AFG, Vreeling FW, Luijckx GJ, Berhey FRJ. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatric Psychiatry 2003;18:552-554.
36. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000;55:1216-1218.
37. Glassman AH, Bigger JT Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Arch Gen Psychiatry 1981;38:815-820.